Pharmacists should reconsider recommending toxic chemotherapy for cancer palliation because it may significantly worsen terminal cancer patients' quality of life near death.
Robert Gaudette, PharmD/MBA Candidate 2016
Advertisement
Articles by Robert Gaudette, PharmD/MBA Candidate 2016
A study evaluating the cardiovascular safety of Merck's type 2 diabetes drug sitagliptin determined the dipeptidyl peptidase-4 inhibitor does not increase the risk for heart failure hospitalization.
Pharmacists know changes in vitamin K intake can drastically alter INR values in patients taking warfarin.
Advertisement
Latest Updated Articles
App Tracks Vitamin K Intake for Warfarin PatientsJune 11th 2015
Diabetes Drug Won't Worsen Heart Failure RiskJune 14th 2015
Palliative Chemo May Worsen QOL Near DeathAugust 16th 2015
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Accepts NDA for AD109 to Treat of Adults With Obstructive Sleep Apnea
2
Men Face Higher Odds of Later-Stage Diagnosis Across 20 Cancer Types
3
Investigational mRNA Flu Vaccine Broadens Antibody Defenses, Sustains Immune "Training Hub" Longer Than Standard Shot
4
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
5